BioCardia, Inc. Common Stock

BCDANASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
1.07 USD
↗ 0.03 (2.40%)🟢LIVE (AS OF 03:20 PM EDT)
🟢Market: OPEN

BioCardia, Inc. Common Stock (BCDA) trades at $1.07 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place BCDA at a fair price relative to peers.

Technical & fundamental data as of Oct 2, 2026.

Open?$1.06
High?$1.07
Low?$1.04
Prev. Close?$1.04
Volume?71.9K
Avg. Volume?300.6K
VWAP?$1.05
Rel. Volume?0.24x
Bid / Ask
Bid?$1.04 × 300
Ask?$1.20 × 100
Spread?$0.16
Midpoint?$1.12
Valuation & Ratios
Market Cap?15.7M
Shares Out?15.1M
Float?8.2M
Float %?71.8%
P/E Ratio?N/A
P/B Ratio?5.83
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Themes
Biotech - Drug Development›Clinical-Stage PlatformsHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
21
Market Cap
15.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.biocardia.com
Listed
1995-10-25
Address
320 SOQUEL WAY
SUNNYVALE, CA 94085
Phone: 650-226-0123
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
45
Piotroski F-Score?0/9Weak
Altman Z-Score?-50.67Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.57%High
Short Interest?863.7K
Days to Cover?4.6
Free Float8.2M
Avg Daily Volume187.4K
Settlement Date2026-09-15
Financial Health
Current Ratio?2.09Strong
Quick Ratio?2.09Strong
Cash Ratio?2.00Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
32
5.83FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-271.8%WEAK▾
ROA?
S&P
3
-154.3%WEAK▾
Cash Flow & Enterprise
FCF?$-7572000
Enterprise Value?$11.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist